PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10
July 31, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Ongoing Phase 1 basket study of PV-10 for cancers of the liver expanded to include single-center cohort of metastatic uveal melanoma patients Presentation of initial metastatic uveal melanoma data...
![webprofile_barrett_am](http://www.globenewswire.com/en/Attachment/LogoDisplay/412656?filename=412656.jpg&size=2)
Participants needed for brain injury research studies at Kessler Foundation
October 19, 2016 11:04 ET
|
Kessler Foundation
EAST HANOVER, N.J., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Kessler Foundation is recruiting study participants for multiple research programs aimed at improving cognition, mobility, and long-term outcomes...
Glycotex, Inc. Obtains Active IND From US Food and Drug Administration for GLYC-101 Wound Healing Compound
January 07, 2008 18:58 ET
|
Glycotex, Inc., Novogen Limited
ROCKVILLE, MD--(Marketwire - January 7, 2008) - Glycotex, Inc. announced today that it had
obtained an active Investigational New Drug Application (IND) from the US
Food and Drug Administration (FDA)...
Research Indicates Synthetic Compound NV-52 May Be Useful in Treatment of Inflammatory Bowel Disease
November 13, 2007 08:04 ET
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - November 13, 2007) - An article published
in a recent edition of the peer review journal Expert Opinion, Vol. 16, No.
8, reveals the compound...
New Data on Novogen Oncology Pipeline to Be Released
October 23, 2007 08:05 ET
|
Novogen
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - October 23, 2007) - New data on the
Novogen oncology pipeline compound NV-128 will be presented on October 23
at the annual AACR/EORTC/NCI...